Multiplex detection and dynamics of IgG antibodies to SARS-CoV2 and the highly pathogenic human coronaviruses SARS-CoV and MERS-CoV

Ayouba, Ahidjo; Thaurignac, Guillaume; Morquin, David; Tuaillon, Edouard; Raulino, Raisa; Nkuba-Ndaye, Antoine; Lacroix, Audrey; Vidal, Nicole; Foulongne, Vincent; Moing, Vincent Le; Reynes, Jacques; Delaporte, Éric; Peeters, Martine

doi:10.1016/j.jcv.2020.104521

Cited by 73 publications

(84 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The observation that RBD slightly outperformed the other spike antigens in a single-plex can be explained by the fact that this region is poorly conserved between different coronaviruses in contrast to the whole spike protein, which might increase RBD’s specificity ( Edridge et al, 2020b , Premkumar et al, 2011 ; Du et al, 2009 ; Ng et al, 2020 ). Consequently, a combination of NP with RBD/S1 is also put forward in two independent Luminex bead-based assays that were recently published ( Dobaño et al, 2020 ; Ayouba et al, 2020 ).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluating SARS-CoV-2 spike and nucleocapsid proteins as targets for antibody detection in severe and mild COVID-19 cases using a Luminex bead-based assay

Mariën

Ceulemans

Míchiels

et al. 2021

Journal of Virological Methods

109

117

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

“…We followed the protocol as described in Ayouba et al 2020 ( Ayouba et al, 2020 ) for the assay. In brief, a microsphere working mixture was prepared in a hypertonic phosphate buffered saline-BSA (PBS-BN) solution with a concentration of 2,000 beads/antigen/well.…”

Section: Methodsmentioning

confidence: 99%

Evaluating SARS-CoV-2 spike and nucleocapsid proteins as targets for antibody detection in severe and mild COVID-19 cases using a Luminex bead-based assay

Mariën

Ceulemans

Míchiels

et al. 2021

Journal of Virological Methods

109

117

View full text Add to dashboard Cite

“…The proteins that form the outer shell of the new coronavirus are protein S (S comes from Spike, the characteristic, spiky appearance of the virus), protein M, membrane protein, and protein E (Envelope). N protein is the nucleocapsid protein that envelops the viral nucleic acid [8].…”

Section: Immunological Endpoints and Clinic-epidemiological Contextmentioning

confidence: 99%

Recent advances, approaches and challenges in targeting pathways for potential COVID-19 vaccines development

et al. 2020

View full text Add to dashboard Cite

During the COVID-19 pandemic in a modern era, there is a global consensus on the need for the rapid development of a vaccine against SARS-CoV-2 for effective and sustainable control. Developing these vaccines is fundamental to public health. This urgent need is supported by the scientific explosion in structural and genomic biology that facilitates the urgent development of an ideal COVID-19 vaccine, using new pathways to facilitate its large-scale development, testing, and manufacture. Here, we summarize the types of COVID-19 candidate vaccines, their current stage in early testing in human clinical trials, and the challenges for their implementation.

show abstract

“…Alternatively, multiplexed testing enables detection of immunoglobulin binding to more than one antigen within a single tube, well, plate or slide. Multiplexed tests include, but are not limited to microsphere immunoassays (MIAs) ( Ayouba et al, 2020 ; Randad et al, 2020 ), fluorescent protein microarrays ( Hedde et al, 2020 ), and direct/label-free array technologies ( Steiner et al, 2020 ).…”

Section: Introductionmentioning

confidence: 99%

Multiplexed detection and quantification of human antibody response to COVID-19 infection using a plasmon enhanced biosensor platform

Cady

Tokranova

Minor

et al. 2021

Biosensors and Bioelectronics

View full text Add to dashboard Cite

The 2019 SARS CoV-2 (COVID-19) pandemic has illustrated the need for rapid and accurate diagnostic tests. In this work, a multiplexed grating-coupled fluorescent plasmonics (GC-FP) biosensor platform was used to rapidly and accurately measure antibodies against COVID-19 in human blood serum and dried blood spot samples. The GC-FP platform measures antibody-antigen binding interactions for multiple targets in a single sample, and has 100% selectivity and sensitivity (n = 23) when measuring serum IgG levels against three COVID-19 antigens (spike S1, spike S1S2, and the nucleocapsid protein). The GC-FP platform yielded a quantitative, linear response for serum samples diluted to as low as 1:1600 dilution. Test results were highly correlated with two commercial COVID-19 antibody tests, including an enzyme linked immunosorbent assay (ELISA) and a Luminex-based microsphere immunoassay. To demonstrate test efficacy with other sample matrices, dried blood spot samples (n = 63) were obtained and evaluated with GC-FP, yielding 100% selectivity and 86.7% sensitivity for diagnosing prior COVID-19 infection. The test was also evaluated for detection of multiple immunoglobulin isotypes, with successful detection of IgM, IgG and IgA antibody-antigen interactions. Last, a machine learning approach was developed to accurately score patient samples for prior COVID-19 infection, using antibody binding data for all three COVID-19 antigens used in the test.

show abstract

Multiplex detection and dynamics of IgG antibodies to SARS-CoV2 and the highly pathogenic human coronaviruses SARS-CoV and MERS-CoV

Cited by 73 publications

References 28 publications

Evaluating SARS-CoV-2 spike and nucleocapsid proteins as targets for antibody detection in severe and mild COVID-19 cases using a Luminex bead-based assay

Evaluating SARS-CoV-2 spike and nucleocapsid proteins as targets for antibody detection in severe and mild COVID-19 cases using a Luminex bead-based assay

Recent advances, approaches and challenges in targeting pathways for potential COVID-19 vaccines development

Multiplexed detection and quantification of human antibody response to COVID-19 infection using a plasmon enhanced biosensor platform

Contact Info

Product

Resources

About